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Over the past two decades, there has been a signiﬁcant amount of research investigating the risks and beneﬁts of hormone
replacement therapy (HRT) with regards to neurodegenerative disease. Here, we review basic science studies, randomized clinical
trials, and epidemiological studies, and discuss the putative neuroprotective eﬀects of HRT in the context of Alzheimer’s disease,
Parkinson’s disease, frontotemporal dementia, and HIV-associated neurocognitive disorder. Findings to date suggest a reduced
risk of Alzheimer’s disease and improved cognitive functioning of postmenopausal women who use 17β-estradiol. With regards to
Parkinson’s disease, there is consistent evidence from basic science studies for a neuroprotective eﬀect of 17β-estradiol; however,
results of clinical and epidemiological studies are inconclusive at this time, and there is a paucity of research examining the
association between HRT and Parkinson’s-related neurocognitive impairment. Even less understood are the eﬀects of HRT on
risk for frontotemporal dementia and HIV-associated neurocognitive disorder. Limits to the existing research are discussed, along
with proposed future directions for the investigation of HRT and neurodegenerative diseases.
1.Introduction
Hormone replacement therapy (HRT), deﬁned here as use
of various types of estrogen alone or in conjunction with
progestins (synthetic or exogenous progestogen), has long
been studied as a possible prophylactic against Alzheimer’s
disease. While the association between HRT and Alzheimer’s
disease has been explored through several observational
and randomized clinical trials to date, the relationship
between HRT and other neurodegenerative diseases has
received relatively little attention. In this review, we explore
the body of research on HRT as a prophylactic against
variousneurodegenerativeconditions,includingAlzheimer’s
disease, Parkinson’s disease, frontotemporal dementia, and
HIV-associated neurocognitive disorder. In reviewing obser-
vational studies, randomized clinical trials, and basic sci-
ence studies, we ﬁnd evidence that some forms of HRT
are neuroprotective, resulting in preservation of cognitive
abilities in healthy postmenopausal women, improvement
of Parkinson’s symptoms, and variably altering risk of
neurodegenerative disease.
2. Alzheimer’s Disease
Alzheimer’s disease (AD) represents the most common
neurodegenerative disease, accounting for more than 50%
of all dementia types [1]. Within the United States alone,
national prevalence estimates indicate that AD aﬀects 2.4
million individuals aged 70 and older [1, 2]. With increasing
age,ADprogressivelyaﬀectsmoreindividuals,aﬀecting2.5%
of those aged 71–79, 18% of those aged 80–89, and 30% of
those aged 90 and older [1, 2].
Cognitive decline in AD is characterized by insidious
onset and gradual progression over a course of several
years [3–5]. Clinical research has identiﬁed subtle losses2 International Journal of Alzheimer’s Disease
of cognitive functioning that precede AD. Studies have
consistently shown that a deﬁcit in episodic or verbal
memory, speciﬁcally the ability to encode novel information,
is an early symptom of AD and often presents several
years before a formal diagnosis of AD [3, 6–9]. Such
observations have led to the identiﬁcation of a preclinical
stage of AD that represents the transition between normal
agingandAD.Speciﬁcally,mildcognitiveimpairment(MCI)
represents the mild neurocognitive decline that occurs in the
presence of relatively intact day-to-day functioning [4, 5].
Although there are several subtypes of MCI, the subtypes
that are at increased risk for the development of AD involve
predominant memory impairment. It has been estimated
that approximately 10–15% of those diagnosed with MCI
with predominant memory impairment convert to AD per
year [4, 5]. The identiﬁcation of MCI as a possible prodrome
to AD, as well as the recent development classiﬁer algorithms
that assess later risk for AD based on a variety of clinical
factors[10], leavesopen the potential for initiating therapies,
including HRT, that may prevent progression to AD in those
at risk.
2.1. Estrogen and Risk for AD—Observational Studies. Inci-
dence rates indicate the risk of AD among women is double
that of men after the age of 80, even after controlling
for protective factors such as education [11]. The higher
incidence rate of AD among women have led to explorations
on the association between estrogen deﬁciency and AD.
Observational studies have examined both HRT and
estrogen replacement therapy (ERT), or estrogen alone, in
relation to incidence of AD (see Table 1). For instance, in a
sampleof514womenenrolledintheBaltimoreLongitudinal
Study of Aging, Kawas et al. found that ERT was associated
with signiﬁcantly reduced risk for AD [12]. Although the
duration of use ranged between 1–15 years, the data did not
show a signiﬁcant eﬀect for duration of ERT. In addition,
no eﬀect was observed for age of menopause. In another
observational study reported by Tang et al., ERT was also
associated with signiﬁcantly reduced risk for AD in a sample
of 1124 women enrolled in the Manhattan Study of Aging
[13]. Here, however, an inverse relationship was observed
for duration of use and risk for AD, with the lowest risk
noted for women taking estrogen for longer than one year.
Otherobservationalstudieshaveprovidedmoderatesupport
for decreased AD risk with ERT and the importance of
duration of use. Using retrospective data on a sample of
355 women, Paganini-Hill and Henderson found that ERT
wasassociatedwithmoderatelyreducedriskfordevelopment
of AD [14]. An inverse relationship was seen for duration
of ERT and risk for all-cause dementia (AD as well as
other causes of dementia), with those on ERT for seven or
more years having the lowest risk for AD. While ﬁndings
from these observational studies suggest that ERT may
reduce risk of AD, given the nature of observational studies
the ﬁndings may be aﬀected by several biases. Speciﬁcally,
the women who decided to take ERT for several years
may have been healthier to begin with; they may have
also been more proactive in seeking early postmenopausal
treatment due to higher education and/or availability of
resources. An additional criticism is the lack of controls in
the studies; for instance, all observational studies described
above involved varied ERT regimens among all participants
ratherthanauniformERTregimen.Thus,theﬁndingsofthe
observational studies present with several limitations.
Althoughallofthestudiesexaminedabovehaveincluded
women who underwent natural menopause, recent observa-
tional studies have examined the diﬀerences between women
who underwent natural versus surgical menopause [15]. In
one, women who had surgical menopause demonstrated an
increased long-term risk for cognitive impairment compared
to women with natural menopause. In another paper
based on the same data, the same researchers reported a
linear trend, with increased risk seen with younger age at
oophorectomy (bilateral or unilateral) [16]. These ﬁndings
suggest that earlier age of surgical menopause increased risk
of cognitive impairment and that estrogen deﬁciency may
initiate risk for neurological diseases such as AD. Notably,
the researchers also found increased risk of depression and
cardiovascular disease among women with history of bilat-
eral oopherectomy, suggesting that the relationship between
surgical menopause and cognitive impairment may be
multifactorial [17, 38].
2.2. Randomized Clinical Trials of HRT in Healthy and At-
Risk Women. While observational studies generally support
a neuroprotective role for ERT against AD, the results of
randomized clinical trials (RCTs) have been equivocal. To
date,thelargeststudyhasbeentheWomen’sHealthInitiative
Memory Study (WHIMS), an ancillary study of the Women’s
Health Initiative (WHI), a prospective study that enrolled
7479 postmenopausal women [39, 40]. A total of 4532
women with natural menopause (intact uterus) were ran-
domized into a trial comparing conjugated equine estrogen
(CEE) + medroxyprogesterone (MPA) versus placebo [40].
However, the trial was discontinued before completion due
to unexpected health risks. Despite the early termination,
data revealed that women who received CEE + MPA
demonstrated greater cognitive decline compared to the
placebo group [40]. Additional analyses revealed that risk
for dementia was doubled for women who received CEE +
MPA compared to the placebo group [39]. Taken together,
data from the WHIMS demonstrated a higher incidence
of dementia and greater cognitive decline among hormone
users relative to placebo groups.
Although the WHIMS has been considered one of the
largest and longest randomized studies examining HRT and
cognitive deﬁcits, generalizability of the ﬁndings is aﬀected
by several limitations. First, external validity of the WHIMS
ﬁndings has come into question, as the participants in the
treatment group were at high risk for cardiovascular and
cerebrovascular disease; thus the higher rates of dementia
mayhavebeenattributedtovasculardisease.Second,intheir
analyses of the WHIMS data, the researchers included all
dementia types into an “all-cause” dementia that included
AD, vascular dementia, dementia due to Parkinson’s disease,
and frontotemporal dementia, thus limiting the interpreta-
tion of results. Third, a methodological limitation included
the unavailability of baseline cognitive measures prior toInternational Journal of Alzheimer’s Disease 3
Table 1: Observational studies of ERT and risk for dementia.
Study (reference) Sample description Overall ﬁndings
Paganini-Hill and
Henderson [14]
355 postmenopausal women (165 users;
190 nonusers) with a mean age of 86.5
years at death; retrospective data from the
Leisure World, Laguna Hills cohort
ERT (not speciﬁed) for 1–7 years was associated with reduced
risk for AD (OR: 0.67, CI 95% 0.38–1.17) compared to
nonusers. Risk for AD decreased with longer duration of use.
Tang et al. [13]
1124 healthy postmenopausal women
(156 users; 968 nonusers), with a mean
age of 74.2, enrolled in the Manhattan
Study of Aging
After controlling for age, education, and ethnicity, ERT
(majority used CEE) for 6–8 years was associated with lower
risk for AD (OR 0.50, 95% CI, 0.25–0.90) compared to
nonusers. Risk for AD decreased with longer duration of use.
Kawas et al. [12]
514 healthy postmenopausal women
(230-users; 242-non-users), with a mean
age of 65.5, enrolled in the Baltimore
Longitudinal Study of Aging
After controlling for education, ERT (not speciﬁed) for 1–10
years was associated with lower risk for AD (OR: 0.46, 95%
CI, 0.21–0.99) compared to non-users. No eﬀect was
observed for duration of use.
Rocca et al.,
[15–17]
813 women with unilateral
oophorectomy, 676 women with bilateral
oophorectomy, and 1,472 women who
did not undergo oophorectomy.
Women who underwent oophorectomy (unilateral or
bilateral) before onset of menopause were at increased risk
for cognitive impairment or dementia (OR: 1.46, 95% CI,
1.13–1.90) compared to women who did not undergo
oophorectomy. Risk increased with younger age at
oophorectomy.
treatment; thus, participants may have already been cog-
nitively impaired prior to beginning HRT. Still another
criticism has been the age of the participants; participants
were age 65 or older, at least a decade past the average age
of menopause. Together, these limitations have called into
question the validity of the WHIMS ﬁndings, suggesting that
the WHIMS may not be the best model for understanding
the eﬀect of HRT on Alzheimer’s disease.
Another limitation in the generalizability of the WHIMS
involves the type of HRT that was used. Speciﬁcally, it has
been pointed out that CEE does not contain the hormone
17β-estradiol, [41] the estrogen compound that has been
shown in basic science studies to be neuroprotective [42–
44]. In addition, the greater rates of dementia seen among
participants of the CEE + MPA study trial of the WHIMS
suggestthatsimultaneoususeofMPAmaypresentadditional
risk [45]. Indeed, consistent with WHIMS ﬁndings, a recent
randomized-controlled study by Maki et al. found that
women receiving CEE + MPA for four months demonstrated
mild declines in verbal memory compared to women
receiving placebo [21]. Additionally, a recent comparison of
several diﬀerent HRT types has provided some insight into
which treatment provides the most cognitive beneﬁt. Using
functional neuroimaging as an outcome measure, Silverman
et al. compared the cerebral metabolic activity associated
with three hormone regimens over the course of one year:
17β-estradiol (E2), CEE, and CEE + progestin [24]. Results
revealed that the E2 group performed signiﬁcantly better
on verbal memory than the CEE group. This group also
demonstrated higher metabolism in the receptive language
and auditory association areas. Additionally, the CEE +
progestin group demonstrated lower metabolism in areas
associated with long-term memory storage (i.e., mesial and
inferior lateral temporal regions) compared to the CEE
group. Taken together, these ﬁndings suggest that E2-based
therapies may provide the most beneﬁcial neuroprotective
eﬀect. In addition, the Silverman et al. study suggests that
combination therapies that include progestin may actually
dampen the beneﬁcial eﬀects of estrogen.
Since the discontinuation of the WHIMS trials, the case
forERTinreducingtheriskforADandimprovingthecogni-
tive functioning of postmenopausal women has continued to
gain at least modest support through further RCTs. Indeed,
resultsfromseveralRCTspublishedinthepastfewyearshave
demonstrated support that E2 formulations are associated
with a reduced amount of decline in verbal memory among
healthypostmenopausalwomenwhencomparedtocontrols.
The beneﬁts of these treatments have been observed in trials
with durations ranging from three months to two years (see
Table 2)[ 18, 22–24]. In contrast, at least one study has found
no beneﬁt on verbal memory associated with E2 compared
to placebo [20]; however, it was noted that the women in
that study used E2 for only two months. Thus, it is possible
that the eﬀects of E2 on verbal memory may be evident only
after three months or more. In a separate study, Joﬀee ta l .
found that E2 was not associated with an improvement in
verbal memory scores but rather decreased likelihood for
errors during the memory tasks [19]. Speciﬁcally, women
on E2 demonstrated less perseverative errors during recall
tasks compared to women on placebo. These women, as a
group, were also less likely to demonstrate an interference
eﬀect when retaining previously learned information. Thus,
although E2 was not found to enhance verbal memory
scores per se, the authors concluded that E2 enhanced verbal
information processing by decreasing the forgetfulness of a
response already given [19].
2.3.NeuropathologicalandNeurophysiologicalStudiesofHRT:
Relevance to AD. While results of recent RCTs show modest
support for a beneﬁcial eﬀect, evidence from histopatholog-
ical and neurophysiological studies has provided stronger
support for estrogen’s neuroprotective eﬀects, particularly
for the neurodegenerative disease process thought to under-
lie AD [46–48]. Neuroimaging and autopsy results have4 International Journal of Alzheimer’s Disease
Table 2: Randomized clinical trials of HRT and verbal memory.
Study
(reference)
Hormone
treatment used
Sample
size Age Outcome
measure Overall ﬁndings
Bagger et al.,
[18]
E2 2mg + varied
progestins versus
placebo for 2 years
261 54.1 Cognitive
screening task
Followup study of women randomized 5, 10
and 15 years earlier to HRT or placebo
during clinical trials. Logistic regression
showed that for women who received HRT
for 2-3 years, the relative risk for cognitive
impairment was signiﬁcant decreased by
64% compared to the never users.
Long-term/current users of HT also
demonstrated a decreased risk of 66%
compared to the never users.
Joﬀee ta l .[ 19]
E2 0.5mg versus
placebo for 12
months
52 40–60 Verbal memory;
Functional MRI
Women on E2 had fewer perseverative
errors during verbal recall when
placebo-treated women. Women on E2 also
showed greater retention of new
information without interference.
LeBlanc et al.,
[20]
Estradiol 2mg
versus placebo for
2m o n t h s
32
53.26
(treatment)
52.08 (placebo)
Verbal memory
Women on estrogen therapy did not show
higher cognitive performance on verbal
memory tasks compared to women on
placebo.
Maki et al., [21]
(CEE) + medrox-
yprogesterone
acetate (MPA)
versus placebo for
4m o n t h s
158 51.9 (treatment)
52.4 (placebo) Verbal memory
Modest negative eﬀects on verbal memory
(short- and long-term recall) were found in
the HRT versus placebo group.
Dumas et al.
[22]
E2 2mg versus
placebo for 3
months
22 50-62 (younger)
70–81 (older) Verbal memory
All women were administered the
antimuscarinic drug scopaline (SCOP) or
placebo. E2 pretreatment signiﬁcantly
decreased the anticholinergic drug-induced
impairments on verbal memory task for the
younger group only compared to the older
group.
Tierney et al.
[23]
E2 1mg versus
placebo for 2 years 142 61–87 Verbal memory
Women on E2 who scored at or above
average showed less decline in delay verbal
memory compared to women on placebo.
Silverman et al.
[24]
17β-estradiol (E2)
versus conjugated
equine estrogen
(CEE) versus CEE
+Pf o r1y e a r
53 50–65 Verbal memory;
FDG-PET
Women on E2 had signiﬁcantly higher
verbal memory than CEE and showed
higher metabolism in Wernicke’s and
auditory association. E2 was also associated
with higher metabolism in mesial and
inferior lateral temporal regions and inferior
frontal cortex compared to PE.
indicated that β-amyloid and tau proteins are involved in the
structural changes that lead to AD pathology, particularly in
the hippocampus and other medial temporal regions, as well
as the parietal and frontal cortical regions [49]. Evidence has
shown that estrogen (particularly E2) provides protection
against β-amyloid-induced damage and tau-related changes
[50]. Observational and RCT studies that also utilized
neuroimaging outcomes have also been supportive of the
beneﬁts of 17β-estradiol, particularly in the brain regions
that show preclinical abnormalities in individuals who are at
risk for AD. For instance, as mentioned earlier, E2 has been
associated with higher metabolism in language processing
and auditory association areas compared to other HRT
regimens(CEEorCEE+MPA)[24].However,observational
studies and RCTs have also demonstrated support for varied
ERT regimens. Compared to nonusers, long-term ERT (E2
or CEE for an average of 15 years) has been associated with
increased cerebral blood ﬂow to the hippocampus and left
superiortemporalgyrusatatwo-yearfollowup[51].Further,
compared to placebo, a four-month trial of ethinylestradiol
and progestin was associated with increased activation in
brain regions associated with the left middle/superior frontal
cortex,andleftinferiorparietalcortexduringverbalmemory
encoding tasks on functional magnetic resonance imaging
[52]. Finally, in another study, long-term users of ERT (E2
or CEE for an average of 18 years) demonstrated higherInternational Journal of Alzheimer’s Disease 5
density of muscarinic receptors in the hippocampus and
prefrontal cortex than individuals who had never used ERT,
suggesting that one of the neuroprotective eﬀects of E2 or
other ERT regimens could also include the maintenance of
thecholinergicsysteminthehippocampusandfrontalcortex
[48].
A recently proposed explanation may explain the incon-
sistent results of the aforementioned observational studies
and RCTs. Known as the “healthy-cell bias” [53], the
hypothesis is that E2 may selectively beneﬁt healthy neurons.
In the context of human studies, based on the ﬁndings from
observational studies and RCTs, this hypothesis predicts
that E2 can be protective if initiated before or during
times of neuronal stress, but harmful if given after the
cells have progressed toward degeneration. In their study,
Chen et al. administered E2 to rat hippocampal neurons
exposed to β-amyloid, using varied doses and dose schedules
(acute versus continuous versus intermittent). Data indi-
cated that neurodegeneration was prevented when E2 was
administered before or during β-amyloid exposure, and a
continuous dose was found to demonstrate the strongest
eﬀects. In contrast, exposure to higher doses of E2 actually
worsened neuronal death when β-amyloid was present.
Additionally, E2 administered after β-amyloid exposure
exacerbated neuronal death. It was concluded that the best
E2 dosing was pretreatment and continuous exposure to
prevent degeneration. Consistent with the “healthy-cell bias”
hypothesis, Dumas et al. demonstrated a selective beneﬁt
of 17β-estradiol toward cognitively intact women [22]. A
group of 142 postmenopausal women (age range: 61–87)
were randomized to receive E2 (n = 70) or placebo (n =
72) for two years. Verbal memory was assessed at baseline
and at 1-year and 2-year followup. Results revealed that
women who received E2 and who performed at or above
average on verbal recall at baseline demonstrated higher
scores at the 1-year and 2-year followup compared to the
placebo group. In contrast, women who received E2 and
performed below average on verbal recall at baseline showed
no signiﬁcant diﬀerence compared to the placebo group.
Dumas et al. concluded that these ﬁndings provided support
to the healthy cell bias hypothesis, as they considered it
improbable that women with a normal score or better
had signiﬁcant neurodegenerative changes [22]. Notably, the
women who beneﬁtted from estrogen exposure were age
70 (average) and approximately 20 years postmenopause,
suggesting that older women who have intact verbal memory
can beneﬁt from a new regimen of ERT late in life, as
long as they have not demonstrated memory impairment.
Interestingly, basic science research has supported the biased
neuroprotective eﬀect of E2 toward healthy individuals; in
fact, the presence of apoplipoprotein E4 (APOE4) genotype
has been found to reduce the neuroprotective role of E2
in an animal model [54]. Thus, an alternative explanation
for the ﬁndings of Dumas et al. could be that the women
who demonstrated lower than average recall at baseline may
have had the APOE4 genotype; in turn, they may have not
experienced the neuroprotective eﬀects of ERT. The healthy
cell bias hypothesis also helps explain the ﬁnding, reported
in most observational studies, of an inverse relationship
between length of HRT treatment and risk for AD.
Other investigators have hypothesized that there may
be a “critical period” for postmenopausal women during
which17β-estradiolselectivelyprovidesabeneﬁcialeﬀectfor
younger as opposed to older women with an intact uterus
[41, 55]. This hypothesis has also received support from at
least one RCT. For example, LeBlanc et al. randomized 22
postmenopausal women to receive either E2 or placebo for
3 months [20]. At the end of the trial, the antimuscarinic
drug scopolamine (SCOP) was administered before a verbal
task to initiate anticholinergic-induced memory impair-
ment. Results showed that E2 pretreatment signiﬁcantly
decreased the anticholinergic-induced impairment on the
verbal memory task for the younger group (age 50–62);
however, the beneﬁt of E2 was not observed in the older
group (age 70–81). Interestingly, the beneﬁcial eﬀects of
E2 were only observed during the anticholinergic challenge
with SCOP and not during the placebo challenge. LeBlanc
et al. concluded that younger women beneﬁt from E2 more
than older women, and that the beneﬁts of E2 in younger
women may be observed only when the cholinergic system
is temporarily disrupted. Consistent with this ﬁnding is
that younger women have a higher density of muscarinic
receptors than older women, and thus may be more sensitive
to cholinergic changes [48]. Thus, it is plausible that the
women in the aforementioned WHIMS may have been past
the “critical period” for the beneﬁcial eﬀects of E2.
2.4. Summary—AD. Taken together, the ﬁndings from stud-
ies employing a variety of methods demonstrate that some
forms of ERT are neuroprotective, resulting in preserva-
tion of cognitive abilities and reduced risk of AD. While
some studies have aﬃrmed that young and healthy post-
menopausal women may beneﬁt the most from estrogen
exposure, other studies have suggested that older and healthy
women with intact verbal memory can also beneﬁt from
estrogen. The consistent ﬁndings from the observational
studiesreviewedaboveseemtobethatERT(mostcommonly
CEE), with a minimal duration of at least one year, is beneﬁ-
cial in reducing risk for AD among healthy postmenopausal
women. Although beneﬁts have been observed among varied
regimens (CEE, CEE + P, E2) [48, 51, 52]; the most
beneﬁcial estrogen formulation seems to be E2 unopposed
by progestin [24, 50]. Randomized clinical trials in healthy,
postmenopausal women have suggested that E2 has been
most beneﬁcial in reducing cognitive decline, particularly
verbal memory, which is the predominant symptom of
early AD [18, 22–24]. Additionally, both observational and
RCT studies utilizing neuroimaging outcomes have been
supportive of the beneﬁts of E2, particularly in the brain
regions that show preclinical abnormalities in individuals
w h oa r ea tr i s kf o rA D[ 21, 24, 51, 52].
3. Parkinson’sDisease
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after AD, with an estimated6 International Journal of Alzheimer’s Disease
prevalence of 0.3% in the general population. Risk increases
with age, with a prevalence of 1% in those over 60, and
4% in those 80 years and older [56]. Many, but not all,
studies have reported higher risk for PD and younger age
of onset in males [57–66]. This observation, along with
the fact that the neuropathological process underlying PD
commonly begins before menopause, suggests that estrogen
may play a modulatory role. In addition, estrogen has a
direct modulatory aﬀects on dopaminergic functioning [67].
Together, these observations suggest a potential protective
eﬀect of estrogen against PD, or ameliorative impact on
symptoms.
3.1. Estrogen and PD Symptoms. A variety of studies have
addressed the impact of estrogen on PD. Perhaps the most
indirect are observational studies of PD symptoms during
the menstrual cycle. Early studies in the 1980s reported
t h a ts o m ef e m a l ep a t i e n t sw i t hP Dh a dﬂ u c t u a t i o n si n
motor symptoms that paralleled presumed ﬂuctuations in
endogenous estrogen levels [68, 69], with presumably lower
levels of estrogen associated with greater motor symptoms.
However, more recent studies have shown mixed results.
Kompoliti et al. did not ﬁnd signiﬁcant correlation between
endogenous hormone levels and motor examination in
the “oﬀ” state (a state of decreased mobility as a result
of nonresponsiveness to medication) among female PD
patients examined at various times during their menstrual
cycle [70].
A small number of prospective studies of ERT and
PD have also been reported, with mixed results (Table 4).
Strijks et al. did not ﬁnd a signiﬁcant dopaminergic eﬀect
in their 8-week placebo-controlled, randomized, double-
blind trial pilot study of E2 in 12 postmenopausal female
patients under the age of 80 [35]. However, an 8-week
double-blind, parallel-group, prospective study using Pre-
marin (CEE) versus placebo in PD patients with motor
ﬂuctuations showed a statistically signiﬁcant improvement
in“oﬀ”times(i.e.,whendopamineagonistmedicationshave
diminished eﬃcacy) among the estrogen treated group [36].
Further, another double-blind, placebo-controlled crossover
study of high-dose transdermal E2 in 8 postmenopausal
women with mild-to-moderate PD demonstrated a slight
anti-Parkinsonian eﬀect without signiﬁcantly worsening
dyskinesias [34].
Although the overall symptomatic eﬀect of ERT on PD
remains unclear, these early studies raised the possibility
that some forms of estrogen may mitigate the symptoms of
PD. Despite this early optimism, a more recent multicenter,
randomized, double-blind, placebo-controlled, pilot trial of
CEEinpostmenopausalwomenwithPDexperiencingmotor
ﬂuctuations did not ﬁnd any beneﬁt of ERT in ameliorating
symptoms [37]. In that study, 23 women received either
0.625mg/day of CEE or matching placebo for 8 weeks.
None of the outcome measures, including changes from
baseline to study completion in Uniﬁed PD Rating Scale
scores, “on” time (i.e., duration that dopamine agonist
medication is eﬀective), dyskinesia ratings, and results
from neuropsychological testing, were signiﬁcantly diﬀerent
between the placebo and treatment groups, although the
authors emphasized a nonsigniﬁcant trend of improvement
on the total and motor scores of the Uniﬁed PD Rating Scale.
It is conceivable that the null ﬁndings were due to the small
sample size; however, the existing literature on ERT and PD
symptoms remains equivocal at this time.
3.2. HRT and Observational Studies of PD Risk. Epidemi-
ological studies of the protective eﬀects of HRT against
PD have been mixed as well (Table 3). The relationship
between lifetime reproductive events and PD was examined
by Martignoni et al. Comparing a large sample of women
diagnosed with PD to healthy controls, they found that
the duration of reproductive life was similar between the
two groups [28]. Time and mode of menopause onset
were also similar between the groups; however, women
with PD reported less access to HRT. In addition, the PD
group overall reported more premenstrual symptoms, fewer
deliveries and abortions, and less use of contraception,
indicating a relationship between PD and reproductive
events.Benedettietal.reportedacase-controlstudyinwhich
women with PD had an earlier reported age of menopause,
a higher frequency of hysterectomies, and lower occurrence
of HRT [27]. Further, Currie et al. found that ERT in
postmenopausal women was associated with a signiﬁcantly
reduced risk of developing PD [29], and Ragonese et al.
found that factors reducing estrogen stimulation during life
were associated with development of PD [30]. Speciﬁcally,
PD was signiﬁcantly associated with shorter fertile life
lengths (<36 years) and a longer cumulative length of
pregnancies (>30 months). This group later reported a
signiﬁcant correlation between age of PD onset and both
age at menopause and fertile life duration [32]. Despite
these ﬁndings, others have found contrary results. Popat et
al. found that the association of postmenopausal HRT and
PD risk depended on the type of menopause [31]. Among
women with history of hysterectomy (with or without an
oopherectomy), ERT use was associated with a 2.6-fold
increased risk for PD, and a trend for additional risk was
noted for increasing duration of estrogen use. Conversely,
among women with natural menopause, no increased risk
of PD was observed with HRT (ERT alone or in conjunction
with progestin). Contrary to the ﬁndings of Benedetti et al.,
earlier age of menopause was associated with reduced risk
of PD. Further, Simon et al. recently reported results of a
22-year prospective study of 244 participants in the Nurses’
Health Study who developed PD [33]. Among their sample,
risk of PD was not signiﬁcantly associated with reproductive
factors or HRT use. However, they did ﬁnd that use of HRT
may modify the associations of smoking and caﬀeine with
PDrisk;speciﬁcally,theinverserelationshipbetweencaﬀeine
use and risk of PD was observed only in non-HRT users.
Further, whereas the researchers also reported an inverse
relationship between pack-years of smoking and risk of PD
for both HRT users and nonusers, risk was reduced more
in the latter group. As such, HRT use appeared to attenuate
the observed beneﬁcial eﬀects of caﬀeine use and tobacco
smoking. Of note, this study did not separately analyze the
data based on type of HRT.International Journal of Alzheimer’s Disease 7
Table 3: Case-control and epidemiological studies of HRT and Parkinson’s disease.
Study
(reference) Sample description Overall ﬁndings
Marder et al.
[25]
87 women with Parkinson’s disease
without dementia (PDND), 80 women
with Parkinson’s disease with dementia
(PDD), and 989 nondemented healthy
women.
ERT reduced risk of dementia among the PD-only sample (OR =
0.22, 95% CI: 0.05–1.0), and also when PDD patients were
compared to healthy controls (OR = 0.24, 95% CI: 0.07–0.78).
ERT did not aﬀect the risk of PD.
Fernandez and
Lapane [26]
Data from 10,145 elderly women with PD
available via the Systematic Assessment in
Geriatric drug use via Epidemiology
(SAGE) database. Included 195 women
with PD who received estrogen and 9950
who did not receive estrogen.
Independent of age, estrogen users had better cognitive
functioning and were more independent with regards to activities
of daily living. More estrogen users were depressed and likely to be
taking antidepressant medications.
Benedetti et al.
[27]
72 women with PD and 72 healthy
women.
The PD group had undergone hysterectomy (with or without
unilateral oophorectomy) more than the control group (OR =
3.36; 95% CI: 1.05–10.77). The PD group had more frequent
occurrence of early menopause (< or = 46 years) (OR = 2.18; 95%
CI: 0.88–5.39). The PD group used ERT for at least 6 months after
menopause less frequently than the control group (14%; OR =
0.47; 95% CI = 0.12–1.85). The PD group did not have earlier
menopause than the control group.
Martignoni et
al. [28]
150 women with idiopathic PD and 300
healthy women, all postmenopausal.
Duration of reproductive life was similar between women with PD
and those without PD. Women with PD reported less access to
HRT. The PD group also reported more premenstrual symptoms,
fewer deliveries and abortions, and less use of contraception,
indicating a relationship between PD and reproductive events
Currie et al. [29] 68 women with PD and 72 healthy
women, all postmenopausal.
50% of women in the control group took ERT, as compared to
25% of women in the PD group. Women who had taken
postmenopausal ERT were less likely to develop PD than those
who had not (odds ratio, 0.40; 95% CI: 0.19–0.84). Among women
with PD, postmenopausal ERT was not associated with age of
onset.
Ragonese et al.
[30]
131 women with idiopathic PD and 131
healthy women.
PD was signiﬁcantly associated with a fertile life length of less than
36 years (OR 2.07; 95% CI: 1.00 to 4.30). PD was also associated
with a cumulative pregnancy length of longer than 30 months (OR
2.19; 95% CI: 1.22 to 3.91). There was an inverse association
between PD and surgical menopause (OR 0.30; 95% CI: 0.13 to
0.77).
Popat et al. [31] 178 women with PD and 189 healthy
women.
Among women with history of hysterectomy (with or without an
oopherectomy), ERT use was associated with a 2.6-fold increased
risk for PD, and a trend for additional risk was noted for increasing
duration of estrogen use. Among women with natural menopause,
no increased risk of PD was observed with HRT (ERT alone or in
conjunction with progestin). Earlier age of menopause was
associated with reduced risk of PD.
Ragonese et al.
[32] 145 women with PD.
A signiﬁcant correlation was found between age at PD onset and
age at menopause, and also between age at PD onset and fertile life
duration.
Rocca et al.
[16, 17]
1,252 women with unilateral and 1,075
women with bilateral ophorectomy, and
2,368 referent women.
Women who underwent either unilateral or bilateral
oophorectomy had an increased risk of parkinsonism compared to
referent women (HR 1.68; 95% CI: 1.06–2.67). This risk increased
with younger age at oophorectomy.
Simon et al. [33]
22-year prospective study of 244 women
with PD enrolled in the Nurses’ Health
Study.
Risk of PD was not signiﬁcantly associated with reproductive
factors or HRT. The association of smoking and caﬀeine with PD
risk was modiﬁed by HRT, however. Based on a very small sample
(4), women using progestin only hormones had increased risk for
PD.8 International Journal of Alzheimer’s Disease
Table 4: RCTs of ERT and Parkinson’s disease.
Study
(reference) Hormone treatment used Sample
Size Outcome measure Overall ﬁndings
Blanchet [34]
High-dose transdermal E2.
Cross-over design with 2
weeks on E2, 2 week
washout, and 2 weeks on
placebo
8 Therapeutic threshold for
levodopa.
All but one participant had
levodopa-induced dyskinesia at start of
study. After 10 days of E2 treatment a
signiﬁcant reduction was observed in the
anti-parkinsonian threshold dose of
intravenous levodopa without signiﬁcantly
worsening dyskinesias
Strijks et al. [35] 17β-estradiol (E2) versus
placebo for 8 weeks 12
Motor score from the Uniﬁed
Parkinson’s Disease Rating Scale
(UPDRS); patient report of
subjective changes.
No diﬀerences in outcome measures
between E2 and placebo.
Tsang et al. [36] C E Ev e r s u sp l a c e b of o r8
weeks 40
UPDRS, timed tapping score,
Hamilton Depression Scale,
patient self-report.
“On” and “oﬀ” times, and motor score on
the UPDRS improved with estrogen.
The Parkinson
Study Group
Poetry I
Investigators
[37]
C E Ev e r s u sP l a c e b of o r8
weeks 23
Primary outcome was ability to
complete the trial. Other
outcome measures included
adverse events, UPDRS, “on”
time, dyskinesia ratings, and
neuropsychological functioning
The estrogen group showed a trend for
improvement on the total and motor
UPDRS scores.
In one of the largest observational studies to date, Rocca
et al. examined 1,252 women with unilateral oophorec-
tomy, 1,075 women with bilateral oophorectomy, and 2,368
controls for development of PD. Data for the partici-
pants were collected until death or the termination of
the study using direct or proxy interviews, neurologic
examinations, medical records, and/or death certiﬁcates.
The authors found that women who underwent either
unilateral or bilateral oopherectomy before the onset of
natural menopause, thereby decreasing endogenous estrogen
levels, had an increased risk of parkinsonism compared with
referent women. Further, risk increased with younger age at
oophorectomy. The ﬁndings were similar regardless of
unilateral or bilateral oopherectomy. Importantly, while the
authors reported a trend, the surgical menopause group was
not at increased risk for PD.
Although these studies might appear to provide conﬂict-
ing results, complex factors are at play. The indication for
HRT (posthysterectomy, posthysterectomy + oopherectomy,
natural menopause), the speciﬁc type of HRT (CEE, E2,
estrogen/progestin combinations), and other variables may
combine in ways yet unknown to increase or decrease PD
risk. Clearly, further study is necessary.
3.3. Studies of HRT and Dementia due to PD. PD is also asso-
ciated with cognitive decline, with anywhere between 24–
31% becoming demented [71]. PD dementia is considered a
subcortical dementia, with associated deﬁcits ranging from
simple motor ability to higher-order cognitive functions
[72]. Despite the high incidence of neurocognitive dysfunc-
tion in PD, the relationship between HRT and dementia in
those with Parkinson’s disease has received considerably less
attention. Only two case-control studies were found. Marder
a n dc o l l e a g u e si n v e s t i g a t e dri s ko fP Db o t hwi t ha n dwi t h o u t
dementia among a sample of 1156 women. They reported
that ERT protected against development of PD-associated
dementia,butnotagainstPDitself[25].Similarly,Fernandez
and Lapane found that estrogen use was associated with
better cognitive functioning and greater independence in
activities of daily living among a large sample of elderly
women living in nursing homes [26]. They also noted that
estrogen users were more depressed and likely to be on an
antidepressant as compared to nonusers. One-year death
rates were comparable between estrogen users and nonusers.
3.4. Mechanisms of Estrogen Action in PD. While epidemi-
ologic, observational, and experimental studies of ERT and
PD have produced equivocal results, the biological mecha-
nisms for a beneﬁcial eﬀect of estrogen upon dopaminergic
functioning are less so. There are two general mechanisms
of action through which estrogen might inﬂuence PD:
symptomatic and neuroprotective. Estrogen receptors have
been located in the nuclei of nigral dopaminergic (DA)
neurons, including estrogen receptor alpha (ERα)a n db e t a
(ERβ)[ 73, 74], suggesting that estrogen might therefore
directly inﬂuence DA functioning. ERα has also been found
inmidbrainglialcells[75],andERβ instriatalmediumspiny
neurons [74]. Novel surface membrane estrogen receptors
have also been described [76, 77]. Perhaps related to these,
administration of exogenous conjugated estrogens results in
anincreaseinbindingoftheDAtransporterligandTRODAT
inotherwisehealthypostmenopausalwomen[78].Ithasalso
been shown that, in the absence of nigral neuroprotection,
central E2 synthesis limits striatal DA loss caused by 6-
OHDA in male rodents, implicating a modulatory eﬀect
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estrogens may upregulate the nigrostriatal pathway, either
pre- or postsynaptically, by an eﬀect on nuclear or surface
membrane estrogen receptors.
Estrogen’s neuroprotective actions have been well
established. In PD, there are animal models that are
exquisitely speciﬁc for nigral cell death, of which the 6-hy-
droxydopamine (6-OHDA) and MPTP/MPP+ models are
perhaps the best known [80, 81]. There is ample evidence
that both endogenous and exogenous estrogen ameliorate
DA depletion in the MPTP/MPP+ model [75, 82–91]. There
is similar evidence that estrogen is neuroprotective in the
6-OHDA animal model [79, 92–96], a methamphetamine
model [97–100], and a wide range of other relevant animal
models [101–103]. The exact mechanisms of neuroprotec-
t i o n ,h o w e v e r ,a r en o tc l e a r .S t u d i e sh a v es h o w nar o l ef o r
binding of estrogen to the nuclear estrogen receptor [104],
the ERα subtype, [105]E R α with a glial contribution, [75]
ERα +E R β [106], and ER-independent mechanisms [88].
This has implications for potential therapeutic agents, as
some estrogen analogues lack activity at one or both nuclear
receptors;whileothers,suchasthe“inactive”enantiomerE2,
may have no ER binding activity at all. E2 has been shown in
the MPTP model to have neuroprotective properties [101],
and has been investigated as a possible neuroprotective agent
[107].
It is important, however, to recognize the imperfect
nature of these preclinical models. First, while PD is a
chronic, slowly progressive disorder, the aforementioned
animal models use agents that cause acute toxicity. Second,
despite the wide use of these models over the past two
decades and the demonstration in preclinical models that
many agents are neuroprotective against 6-OHDA, MPTP, or
both, none of these agents have proven neuroprotective in
human subjects with PD. There may be a simple explanation
for this. We now know that neurodegeneration in most cases
of familial PD is due to impaired ubiquitin-proteosomal
function and alpha-synuclein protein aggregation [108].
Although the relationship between these abnormalities and
those replicated by the 6-OHDA and MPTP models are
complex, it appears likely that any agent that will be
neuroprotective in humans with idiopathic PD will need
to act to reduce alpha-synuclein aggregation. This can
occur either by reducing its synthesis, reducing protein
aggregation, enhancing its elimination, or reducing the
toxic eﬀects of excessive alpha-synuclein. Only recently
has evidence been found that estrogen has the ability to
act on alpha-synuclein in a beneﬁcial manner. Hirohata
et al. found a variety of sex hormones, including estriol,
estradiol, estrone, androstenedione, and testosterone to exert
signiﬁcant antiaggregation and ﬁbril-destabilizing eﬀects on
alpha-synuclein in vitro. Estradiol was especially eﬀective
[109]. Further, Marwarha et al. showed that activation of
ERβ, in conjunction with inhibition of LXRβ,m a yr e d u c e
progression of PD by slowing α-synuclein accumulation.
3.5. Summary—PD. While in vitro and non-human in vivo
experiments have consistently demonstrated evidence for
estradiol’s neuroprotective activity in dopaminergic neurons
and animal models of PD, results of clinical and epidemio-
logical studies are inconclusive at this time. Recent ﬁndings
of estradiol’s modulation of alpha-synuclein indicate a
speciﬁc mechanism through which the hormone may reduce
risk for PD and/or mitigate symptoms. Longer clinical trials
with speciﬁc estrogen compounds (i.e., 17β-estradiol), as
well as biological markers of disease progress (e.g., neu-
roimaging), will be more likely to deﬁnitively determine if
ERT is protective against PD or if it can mitigate the disease.
With speciﬁc regards to PD-associated dementia, only two
case-control studies were located, both suggesting that ERT
reduces risk of cognitive impairment in women with PD.
4.HIV-AssociatedNeurocognitive
Disorder (HAND)
Internationally, an estimated 33 million individuals have
HIV/AIDS, [110] and in many areas women comprise the
majority of those infected [111]. Aggressive intervention
with a regimen of multiple antiretroviral drugs (combined
antiretroviral therapy, or cART) has successfully increased
lifespan and attenuated some of the most dire neurological
eﬀects of HIV infection. However, cART cannot eradicate
HIV, and it has attenuated, not eliminated, the most com-
mon neurological complication of HIV, or HIV-associated
neurocognitive disorder (HAND) [112]. In this section, we
discuss what is known about estrogen and HAND from
observational studies in humans, studies in animal models,
and in vitro studies. No relevant human clinical trials of
estrogen for HAND have been published.
HANDisaconstellationofcognitiveimpairmentscaused
by HIV infection [112]. Because of the lack of diagnostic
biomarkers, HAND remains largely a clinical diagnosis,
made when an HIV+ individual experiences neurocognitive
decline, sometimes with concomitant deﬁcits in day-to-day
functioning,andonlyafterotherconditionsthatmightcause
this decline have been ruled out. The severity of HAND
ranges between mild neurocognitive impairment with no
impact on day-to-day functioning to a debilitating HIV-
associated dementia [112]. While the incidence of new cases
of HAD has declined dramatically [113, 114], the prevalence
of milder forms of HAND has actually increased along
with the longevity of the cART-treated HIV+ population
[113]. This phenomenon has been variously ascribed to
several explanations, including the presence of irreparable
CNS damage pre-cART [115], the failure of many cART
regimens to adequately penetrate and treat the CNS [116],
persistent low levels of HIV despite treatment [117], and to
persistentCNSinﬂammation[118],amongothers.Thelatter
is particularly relevant to the putative therapeutic beneﬁt of
estrogen, as it appears that cART does not always reduce and
insomecasesmayincrease,theCNSinﬂammation[119]that
isassociatedwithHAND[120].Estrogenhassigniﬁcantanti-
inﬂammatory and neuroprotective properties [121–123]a n d
can potentially counteract inﬂammation in the HIV+ brain,
as discussed in more detail below.
There are several other important reasons for investi-
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HIV and HAND. First, estrogen and other gonadal steroids
have signiﬁcant eﬀects on the course and presentation of
HIV disease itself. For example, women are at increased risk
for acquiring HIV compared to men, and this vulnerability
may be aﬀected by gonadal hormones [124]. Further, in
a macaque model of HIV infection, progestogen-based
hormonal contraceptives increased the risk of acquiring
simian immunodeﬁciency virus (SIV), increased disease
progression, and increased genital shedding of SIV; whereas
treatment with estrogen lowered risk of acquiring SIV [125].
Results of natural history studies suggest a gender role in
disease progression, possibly due to hormonal diﬀerences.
For example, women have lower HIV RNA viral loads at
seroconversion compared to men [126], and when adjusted
for CD4+ count, women have lower viral loads throughout
the course of their infection [127]. While one study found
a lower risk of clinical progression to AIDS among HIV+
women versus HIV+ men treated with cART [128], others
have found no diﬀerences in clinical outcome by gender
[129]. A possible explanation for such gender disparity,
should it turn out to be valid, is estrogen, which decreases
HIVreplicationinperipheralbloodmononuclearcells[130].
However, all such studies must be interpreted with caution
because of the reported gender diﬀerences between HIV+
men and women in socioeconomic status, risk behavior,
substance abuse, and access to care [131], which also aﬀect
progression to AIDS [132, 133]. With regards to HAND,
whether women develop HAND at the same rate as men
or if there are diﬀerent clinical manifestations of HAND in
men and women remains a controversial topic. In part, this
isbecausesofewstudies hadsuﬃcient numbers of femalesto
evaluate.Asub-studyoftheWomen’sInteragencyHIVStudy
is beginning to address this problem [134].
There is neurobiological reason to expect a reduction
of HIV-related neuropathological changes with ERT. Firstly,
microglia are the resident immune cells of the CNS, and
these cells play an important role in driving inﬂammation
in many neurodegenerative diseases, thus representing an
important target for therapy [135]. In HIV infection,
microglia can be infected and/or activated; they are major
sources of complete HIV virions, individual neurotoxic viral
proteins, proinﬂammatory substances, and other potential
mechanisms that drive neurotoxicity, neuroinﬂammation,
oxidative stress, and neurodegeneration. Microglia express
endogenous estrogen receptors [136], and treatment with
estrogen is anti-inﬂammatory provided it is administered
early in the course of an insult [121, 123]. Secondly, estro-
gen’s anti-inﬂammatory eﬀects may directly counteract the
neuroinﬂammation caused by HIV proteins. HIV-infected
cells can generate both replication-competent virions and
excess viral proteins, which are shed or secreted into
the extracellular space. The HIV coat protein, gp120,i s
the binding protein for viral entry [137] and acts as an
indirectneurotoxinviaitseﬀectsonmicroglia,macrophages,
and astrocytes, initiating a cascade of events that damage
neurons. Estrogen has been reported to have a broad anti-
inﬂammatory eﬀect on microglia [121]. Estrogen reduces
the neuroinﬂammatory responses to gp120 and exerts neu-
roprotective eﬀects on gp120-exposed neurons, by raising
the levels of neurotrophins, decreasing apoptotic factors, and
antioxidant properties [138]. Zemlyak et al. reported two
diﬀerent beneﬁcial eﬀects of estrogen in the amelioration
of gp120-induced toxicity: a major eﬀect of attenuating the
neurotoxicity of factors released by gp120-treated microglial
cultures, and a minor eﬀect of enhancing the ability
of neuronal cultures to survive exposure to neurotoxic
factors [122]. Another neurotoxic HIV protein, tat, the
nuclear trans-activating protein, is essential in promoting
the transcription and replication of HIV. tat can act both
directly to harm neurons [139], and indirectly by stimulating
macrophages, microglia, and astrocytes to synthesize harm-
ful substances such as proinﬂammatory cytokines [140], and
by increasing free radicals and oxidative stress [141]. In cell
culture, 17β-estradiol suppressed tat-activated transcription
of HIV in astrocytes [142]. 17β-estradiol also attenuated
the tat-induced release of pro-inﬂammatory mediators in
endothelial cells [143], prevented oxidative stress and cell
death associated with combined gp120 and tat neurotoxicity
in vitro [144], and prevented gp120/tat-induced loss of
dopamine transporter function [144].
These observations have led to the proposal that serum
estradiol levels be maintained in HIV+ women as a possible
neuroprotective agent against HAND [145]. Despite this,
there is little clinical information about estrogen and HAND
in HIV+ women. A single retrospective study from the pre-
cARTera,of84older(age40+years)HIV+women,reported
that hormone replacement therapy (HRT) was associated
with a signiﬁcantly decreased risk of mortality [146]. Of
interest, there were six women in the cohort who were
diagnosed with HIV-associated dementia, none of whom
reported taking HRT. This study has been interpreted by
some to indicate a neuroprotective eﬀect of HRT; however,
this was not a prospective study that examined cognition in
anorganizedorstandardizedfashion.However,basedonthis
last report and on the neuroprotective role of estrogen in
other inﬂammatory and degenerative conditions, the role of
estrogen and other hormones in HAND has become an area
of growing interest among basic scientists.
No studies of HAND or neurocognitive functioning
in HIV+ persons have considered hormonal status or use
of exogenous hormones. The preponderance of evidence
to date indicates that HIV+ men and women develop
neurocognitive impairment at a similar rate, when issues
suchasaccesstocare,education,andsubstanceabusehistory
are similar. While some have reported a higher occurrence of
HIV-associated dementia among women [147], others have
notfoundthis[148,149].Morerecently,Martinetal.studied
a large well-matched group of adult male and females, strati-
ﬁedbyHIVstatus,allwithahistoryofsubstancedependence
[150]. Participants were abstinent at the time of testing.
Whereas the performance of HIV+ men did not diﬀer from
HIV-negative counterparts of measures of motor skill and
probabilistic learning, the HIV+ women performed worse
than their seronegative counterparts, suggesting that women
mightbemor evulnerablet otheeﬀectsofHIV.However,due
to the absence of a nonsubstance-dependent control group,
they could not exclude the possibility that the observed
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cognitive eﬀects of addiction. Another study reported no
gender diﬀerence in rate of neurocognitive decline over time
[151]; and still another found that while rates of impairment
were similar between men and women, there were some
diﬀerencesin theneurocognitive proﬁles[148].Whether this
is related to estrogen or other gonadal hormones remains to
be determined.
4.1. Summary—HIV/HAND. HAND shares many features
with other neurodegenerative diseases, including microglial
activation and neuroinﬂammation. Preliminary studies in
animal and in vitro models indicate that, like many other
neurodegenerative diseases, the eﬀect of HIV on the brain
may be blunted by treatment with 17β-estradiol, and possi-
bly other gonadotrophic hormones. This would have to be
balanced against the risks of adding estrogen to the regimens
of HIV+ patients, both male and female. However, there is a
pressing need to determine if HRT may beneﬁt patients with
AIDS who remain at risk for HAND even when treated with
HAART.
5. Frontotemporal Dementia
Frontotemporal dementia, or FTD, is the most common
form of a group of related neurodegenerative diseases that
primarily aﬀect the frontal and/or temporal lobes. The
others include semantic dementia and progressive nonﬂuent
aphasia. Collectively, these have been called frontotemporal
lobar degenerative diseases [152], and they are believed
to account for an estimated 20% of dementia cases with
presenile onset [153].
Only one study to date has addressed the relationship
between HRT and FTD. Levine and Hewett reviewed the
medical ﬁles of all women seen at an Alzheimer’s disease
center (ADC) in Central California and found that 70% of
women diagnosed with FTD had been taking HRT (exact
regimen unspeciﬁed) when evaluated, as compared to an
estimated 24% of the surrounding population [154]. While
one easy interpretation would be that women exhibiting
cognitive impairment would have been more likely to be
placed on HRT before coming to the ADC, only 20%
of women diagnosed with AD at the same center had
been taking HRT, so it is therefore unlikely that HRT was
administered as a result of preclinical cognitive problems.
The women diagnosed with FTD were also similar in age to
womenenteringthecenterwithAD(averageageofsymptom
onset was 65, average age of initial evaluation was 70). While
poor diagnostic accuracy and estrogen’s beneﬁcial eﬀects on
mood were cited as possible reasons for the ﬁndings, a more
compelling reason oﬀered was a marked upregulation of
tau in response to E2 administration, as evidenced in vitro
[155]. The neuropathological correlates of many FTD cases
appear to be tau-related, and in some cases directly linked
to mutations in the tau gene [156]. In such cases, E2 may
increase risk of FTD by increasing production of mutated
forms of tau. However, while the role of tau in FTD has been
well established, it is now known that it does not account
for all forms of FTD [157]. Still the relationship between tau
and E2 is a compelling reason to further study the inﬂuence
of ERT on risk for FTD.
6. Summary and Conclusions
In summarizing the evidence discussed above, HRT, in
particular ERT, appears to play an eﬃcacious role in treat-
ing and preventing several neurodegenerative conditions.
Figure 1 depicts putative neurobiological and neurobehaivo-
ral sequelae resulting from 17β-estradiol use, based on
studies reviewed in this paper. The case for a neuroprotective
role of HRT and AD is supported by research from epidemi-
ological and RCT studies, which have shown that estrogen,
speciﬁcally E2 (17β-estradiol), can reduce the risk for AD
and minimize cognitive decline in otherwise healthy women,
particularly verbal memory. Based on basic science research,
the mechanisms for this neuroprotection may involve E2’s
protectionagainstβ-amyloid-induceddegenerationandmay
even include the maintenance of the cholinergic system in
the hippocampus and frontal cortex. In addition, at least one
study has demonstrated that the presence of progestins in
combination therapies may actually dampen the beneﬁcial
eﬀects of estrogen [24].
Similarly, in vitro and non-human in vivo experiments
have demonstrated E2’s neuroprotective eﬀects in dopamin-
ergic neurons and animal models of PD. In addition, E2’s
modulation of alpha-synuclein indicates a speciﬁc mecha-
nism through which the hormone may reduce risk for PD
and/or mitigate symptoms. To date, results of clinical and
epidemiological studies of ERT alleviating motor symptoms
in PD patients have been mixed and warrant further
investigation. The eﬀects of HRT on the neurocognitive
symptoms of PD have received little attention, with the two
case-control studies to date indicating that ERT reduces risk
of cognitive impairment in women with PD.
Preliminary studies in animal and in vitro mod-
els indicate that treatment with E2, and possibly other
gonadotrophic hormones, may reduce the eﬀect of HIV on
the brain. To date, much research on the neuroprotec-
tive eﬀects for HIV neurodegenerative changes has been
conducted on animal models and has yet to extend to
humans. Nonetheless, preliminary research has suggested
that development of HAND may be alleviated by HRT
pretreatment. Conversely, and contrary to the ﬁndings from
otherneurodegenerativediseases,thereissomeevidencethat
E2 may actually augment risk for FTD via its action on tau.
Additional research is needed to further delineate the
molecular mechanisms through which E2 and other estro-
gens act to delay or prevent neuropathological progres-
sion, or possibly cause progression in the case of FTD.
Large-scale observational studies that accurately document
HRT regimen and control for factors such as depression,
education, and medical comorbidities (e.g., vascular risk
factors) will also help to elucidate the role of ERT in
the neurodegenerative disease etiology. While observational
studiesandRCTsexaminingERTandADhavedemonstrated
long-term beneﬁcial eﬀects of varied ERT regimens (E2 or
CEE), future studies may include long-term followup (5–
10 years) of E2-based therapies alone on cognitive measures12 International Journal of Alzheimer’s Disease
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Figure 1: Putative mechanisms through which 17β-estradiol exerts neuroprotective and neuro-adverse eﬀects. In the context of Alzheimer’s
disease, Parkinson’s disease, and HIV, 17β-estradiol appears to be neuroprotective. However, frontotemporal dementia is often the result of
mutated tau protein and/or tau-related pathology. Because 17β-estradiol increases production of tau, it may accelerate risk for some forms
of frontotemporal dementia.
and neuroimaging outcomes, as such would provide helpful
information on the duration of the beneﬁts of E2 following
discontinuation.
Notably, possible medical risks should be considered
in study of HRT and neurocognitive functioning [45]. For
instance, breast cancer is often a substantial concern that
is linked with HRT. In fact, it is claimed that combined
HRT with estrogen plus progestin is a cause for breast
cancer. However, while followup analysis approximately
three yearsaftertermination of the WHI study demonstrated
an increased risk for “all-cause cancer” for participants in
the CEE + MPA trial compared to the placebo group [158],
the risk for breast cancer and other types of cancer did not
diﬀerbetweengroups.Similarly,recentretrospectiveanalyses
of the WHI data found insuﬃcient evidence that estrogen
plus progestin increased risk of breast cancer [159]. Another
study using the WHI data found that among women in the
CEE + MPA trial, increased breast cancer risk was especially
pronounced among women with breast tenderness [160]. In
fact, new onset of breast tenderness after HRT initiation was
associated with increased breast cancer risk among women
assigned to the CEE + MPA trial, but not among women
assigned to CEE-alone. In contrast, an additional followup
analyses afterthe termination of the WHI data demonstrated
that participants in the CEE-alone trial did not demonstrate
increased risk for breast cancer [161]. Although the available
information is insuﬃcient at this time to support a clear link
between HRT and increased risk for breast cancer, at least
one study from the WHI has reported an increased risk of
breast cancer among users of estrogen plus progestin with
new onset of breast tenderness. This is an issue that requires
continued investigation.
In clinical settings, the ﬁnancial cost will need to be
considered when recommending E2-based therapies for pre-
vention of AD or other neurodegenerative diseases. Patients
and their physicians will have to determine whether the
potential cognitive beneﬁt associated with E2 will outweigh
the ﬁnancial cost, as well as the above-mentioned medical
risks.
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